Carbamazepine clearance in hemodialysis and hemoperfusion

DICP. 1989 Feb;23(2):137-40. doi: 10.1177/106002808902300206.

Abstract

A 47-year-old woman with endstage renal disease and dialysis-induced encephalopathy was being treated with carbamazepine for myoclonus. Her carbamazepine serum concentration appeared to be therapeutic at 5.1 micrograms/ml. She experienced a seizure while on hemodialysis/hemoperfusion that was possibly related to the removal of carbamazepine during dialysis. The elimination of carbamazepine on a dialysis day was compared with elimination on a nondialysis day. The half-life and apparent clearance were the same for each day, indicating that hemodialysis/hemoperfusion had little effect on the overall removal of carbamazepine from the body. The possible reasons for this lack of effect are discussed.

Publication types

  • Case Reports

MeSH terms

  • Carbamazepine / blood
  • Carbamazepine / pharmacokinetics*
  • Carbamazepine / therapeutic use
  • Female
  • Hemoperfusion* / adverse effects
  • Humans
  • Kidney Failure, Chronic / metabolism*
  • Kidney Failure, Chronic / therapy
  • Metabolic Clearance Rate
  • Middle Aged
  • Myoclonus / drug therapy
  • Renal Dialysis / adverse effects*

Substances

  • Carbamazepine